Biomarkers in migraine: Their promise, problems, and practical applications

Headache

Volumn 46, Issue 7, 2006, Pages 1046-1058

  Loder, Elizabeth ^a,b   Rizzoli, Paul ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NONE   (United States)

Author keywords

Biomarkers; FDA; Metabolomics; Migraine; Pharmacogenomics; Proteomics

Indexed keywords

BIOLOGICAL MARKER;

DIAGNOSTIC VALUE; DISEASE COURSE; HIGH RISK POPULATION; HUMAN; LEGAL ASPECT; MEASUREMENT; MIGRAINE; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; RELIABILITY; REVIEW; VALIDITY;

ANIMALS; BIOLOGICAL MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIGRAINE DISORDERS; POLYMORPHISM, GENETIC; SENSITIVITY AND SPECIFICITY;

EID: 33745606046     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2006.00498.x     Document Type: Review

References (52)

1. Lesko LJ, Atkinson AJ. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: Criteria, validation, strategies. Ann Rev Pharmacol Toxicol. 2001;41:347-366.
2. Mayeux R, Saunders AM, Shea S, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's disease centers consortium on apolipoprotein E and Alzheimer's disease. N Engl J Med. 1998;338:506-511.
3. Ladenson PW. Optimal laboratory testing for diagnosis and monitoring of thyroid nodules, goiter, and thyroid cancer. Clin Chem. 1996;42:183-187.
4. Detels R, Tashkin DP, Simmons MS, et al. The UCLA population studies of chronic obstructive respiratory diseases. Agreement and disagreement of tests in identifying abnormal lung function. Chest. 1982;82:630-638.
5. Packer CS. Biochemical markers and physiological parameters as indices for identifying patients at risk of developing pre-eclampsia. J Hypertens 2005;23:45-46.
6. International Classification of Headache Disorders II. Cephalalgia. 2004;24(suppl 1):1-160.
7. Loder E, Biondi D. Disease modification in migraine: A concept that has come of age? Headache. 2003;43:135-143.
8. Loder E, Sheftell F. The quality of headache care in the United States: Review and analysis of recent data. Headache. 2005;45:939-946.
9. Rose G. Sick individuals and sick populations. Int J Epidemiol. 2001;30:427-432.
10. Hampton T. Clinical trials point to complexities of chemoprevention for cancer. Med News Perspectives JAMA. 2005;294:29-31.
11. Kaiser J. Genomic databases. NIH goes after whole genome in search of disease genes. Science. 2006;311:933.
12. Vanmolkot KR, Kors EE, Turk U, et al. Two de novo mutations in the Na, K-ATPase gene ATP1A2 associated with pure familial hemiplegic migraine. Eur J Hum Genet. 2006;14:555-560.
13. Kosmeder JW II, Pezzuto JM. Intermediate biomarkers. Cancer Treat Res. 2001;106:31-61.
14. Drumm ML, Konstan MW, Schluchter MD, et al. Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med. 2005;353:1443-1453.
15. Rodenhiser D, Mann M. Epigenetics and human disease: Translating basic biology into clinical applications. CMAJ. 2006;174:341-348.
16. Weaver IC, Cervoni N, Champagne FA, et al. Epigenetic programming by maternal behavior. Nat Neurosci. 2004;7:847-854.
17. Sevignani C, Calin GA, Siracusa LD, Croce CM. Mammalian microRNAs: A small world for fine-tuning gene expression. Mamm Genome. 2006;17:189-202.
18. Lu J Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435:834-838.
19. Haston CK, Hudson TJ. Finding genetic modifiers of cysticfibrosis. N Engl J Med. 2005;353:1509-1511.
20. Green ED, Waterston RH. The human genome project: Prospects and implications for clinical medicine. JAMA. 1991;266:1966-1975.
21. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: Opportunities and potential limitations. Mol Cell Proteomics. 2004;3:367-378.
22. Bearer CF. Markers to detect drinking during pregnancy. Alcohol Res Health. 2001;25:210-218.
23. Fin OJ. Immune response as a biomarker for cancer detection and a lot more. N Engl J Med. 2005;353:1288-1290.
24. Klerman EB, Gershengorn HB, Duffy JF, Kronauer RE. Comparisons of the variability of three markers of the human circadian pacemaker. J Biol Rhythms. 2002;17:181-193.
25. Bramanti P, Grugno R, Vitetta A, Marino S, Di-Bella P, Nappi G. Ietal and interictal hypoactivation of the occipital cortex in migraine with aura. A neuroimaging and electrophysiological study. Funct Neurol. 2005;20:169-171.
26. Franceschi M, Colombo B, Rossi P, Canal N. Headache in a population-based elderly cohort. An ancillary study to the Italian Longitudinal Study of Aging (ILSA). Headache. 1997;37:79-82.
27. Mazzotta G, Ballai V, Alberti A, et al. Characteristics of migraine in an out-patient population over 60 years of age. Cephalalgia. 2003;23:953-960.
28. Plosker GL, Keam SJ. Trastuzumab: A review of its use in the management of HER2-positive metastatic and early-stage breast cancer. Drugs. 2006;66:449-475.
29. Guidance for Industry: Pharmacogenomic Data Submissions. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research, Center for Biologies Evaluation and Research, Center for Devices and Radiological Health. March 2005. Available at URL http://www.fda.gov/CBER/gdlns/pharmdtasub.pdf on April 26, 2006.
30. International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: Second edition. Cephalalgia. 2000;20:765-786.
31. Biomarker study can save Iressa. Reed Life Science News. Available on www.genpromag.com/-ShowPR~PUBCODE~018~ACCT~180000010~ ISSUE~0503~RELTYPE~RLSN~PRODCODE ~00000000~PRODLETT~E.html. Accessed online April 12, 2006.
32. Pollack A. A special drug just for you, at the end of a long pipeline. New York Times, Tuesday, November 8, 2005.
33. Silberstein SD, Goadsby PJ. Migraine: Preventive treatment. Cephalalgia. 2002;22:491-512.
34. Taube SE, Jacobson JW, Lively TG. Cancer diagnostics: Decision criteria for marker utilization in the clinic. Am J Pharmacogenomics. 2005;5:357-364.
35. Mancini GB, Schulzer M. Reporting risks and benefits of therapy by use of the concepts of unqualified success and unmitigated failure: Applications to highly cited trials in cardiovascular medicine. Circulation. 1999;99:377-383.
36. Schulte PA, Perera FP. Validation. In: Schulte PA, Perera FP, eds. Molecular Epidemiology: Principles and Practices. San Diego: Academic Press; 1993:79-107.
37. Pepe MS, Thompson ML. Combining diagnostic test results to increase accuracy. Biostatistics. 2000;1:123-140.
38. Thompson ML, Zucchini W. On the statistical analysis of ROC curves. Stat Med. 1989;8:1277-1290.
39. Haker S, Wells WM, Warfield SK, et al. Combining classifiers using their receiver operating characteristics and maximum likelihood estimation. Lecture Notes in Computer Science 2005; Volume 3749: 506-514. Published proceedings of MICCAI 2005: 8th International Conference, Palm Springs, CA, October 26-29, 2005. Editors: James S. Duncan, Guido Gerig. Available on http://spl.harvard. edu:8000/pages/papers/haker/haker-miccai2005.pdf. Accessed online May 3, 2006.
40. Rubenstein JH. The cost-effectiveness of biomarkers for predicting the development of oesophageal adenocarcinoma. Aliment Pharmacol Ther. 2005;22:135-146.
41. Porter A, Gladstone JP, Dodick DW. Migraine and white matter hyperintensities. Curr Pain Headache Rep. 2005;9:289-293.
42. Dalla Volta G, Guindani M, Zavarise P, et al. Prevalence of patent foramen ovale in a large series of patients with nigraine with aura, migraine without aura and cluster headache, and relationship with clinical phenotype. J Headache Pain. 2005;6:328-330.
43. Mayeux R. Biomarkers: Potential uses and limitations. NeuroRx. 2004;1:182-188.
44. Antecedent biomarkers in Alzheimer's disease: Uses, limitations, and future directions for research. Available on http://www.alzforum.org/res/enab/ workshops/bioma-rkers.asp. Accessed online April 13, 2005.
45. O'Reilly J, Dalal A. Off-label or out of bounds? Prescriber and marketer liability for unapproved uses of FDA-approved drugs. Ann Health Law. 2003;96:429-431.
46. Hirst G. Consent before testing men for prostate cancer - a challenge? Aust Fam Physician. 2005;34:889-891.
47. Stix G. Owning the stuff of life. Sci Am. 2006;294:76-83.
48. Jensen K, Murray F. Intellectual property landscape of the human genome. Science. 2005;310:239-240.
49. Grisham J. New rules for gene patents. Nat Biotechnol. 2000;18. Available on http://www.biotech-info.net/new_rules.html. Accessed online April 14, 2006.
50. Marris E. Free genome databases finally defeat Celera. Nature. 2005;435:6.
51. Matthijs G. The European opposition against the BRCA gene patents. Fam Cancer 2006;5:95-102.
52. Ruttimann J. US to rule on research patent. Nature 2006;440:587.